Organisation paid for research Program year 2025 Source: CMS Open Payments

Community Research

Neither a doctor nor a teaching hospital

Research payments

$737,771

684 payments

Through program year 2025, Community Research is reported as receiving $737,771 in research payments, across 684 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $15,195 1
2024 Research $10,442 3
2023 Research $78,415 6
2022 Research $496,812 652
2021 Research $40,648 4
2020 Research $92,759 17
2019 Research $3,500 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $370,157 650 payments
  2. Harmony Biosciences LLC $249,334 13 payments
  3. H. Lundbeck A S $99,587 19 payments
  4. AstraZeneca Pharmaceuticals LP $15,195 1 payment
  5. Avanir Pharmaceuticals, Inc. $3,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $369,558 649 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension $239,490 11 payments
  3. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $42,891 3 payments
  4. A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing An Acute Attack of Migraine $36,166 12 payments
  5. Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With An Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments $20,530 4 payments
  6. A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA $15,195 1 payment
  7. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension $9,844 2 payments
  8. 15-Avp-786-303 $3,500 1 payment
  9. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $599 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record